Command Palette

Search for a command to run...

Failure Claims

Indexed failure dossiers with primary-source backing.

196 claims indexed
TitleTargetTrialPhaseFailure
Oct 10, 2026Ataluren and the subgroup that did not travel: a 15-year extension closes without an efficacy endpointAtalurenDMDPTC TherapeuticsNCT01247207Phase 3SponsorOther
Oct 10, 2026Eniluracil, 24 years later: a target validated for drug handling, retested for disease biologyPCS6422 (eniluracil) plus capecitabineDPYDProcessa PharmaceuticalsNCT06568692Phase 2SponsorOncology
Oct 4, 2026SAR444881 and the 2-of-6 problem: an anti-ILT2 antibody that never beat its own confidence intervalSAR444881LILRB1SanofiNCT04717375Phase 1/2EfficacyOncology
Oct 4, 2026Casdozokitug in hepatocellular carcinoma: a randomized phase that was designed, funded and never runCasdozokitugIL27Coherus Oncology, Inc.NCT05359861Phase 2SponsorOncology
Oct 3, 2026Strong genetics, weak endpoint: the OX40L asthma programme ends with RIVER-ASTHMAAmlitelimabTNFSF4SanofiNCT06033833Phase 2SponsorOther
Oct 3, 2026Who was allowed in: KEYNOTE-630 and adjuvant PD-1 blockade in cutaneous squamous cell carcinomaPembrolizumabPDCD1Merck Sharp & Dohme LLCNCT03833167Phase 3EfficacyOncology
Oct 2, 2026Positive and discontinued: forimtamig, GPRC5D and the cost of being secondForimtamig plus carfilzomibGPRC5DHoffmann-La RocheNCT06055075Phase 1/2SponsorOncology
Oct 2, 2026Twice at scale: KEYNOTE-991 and PD-1 blockade in hormone-sensitive prostate cancerPembrolizumab plus enzalutamide and androgen deprivation therapyPDCD1Merck Sharp & Dohme LLCNCT04191096Phase 3EfficacyOncology
Oct 1, 2026A single-arm median is not a comparator: SAPPHIRE and TAM-directed checkpoint rescueSitravatinib plus nivolumabAXLMirati Therapeutics Inc.NCT03906071Phase 3Translational MismatchOncology
Oct 1, 2026Deuterium is not free: AVP-786 and the null result in negative symptoms of schizophreniaAVP-786 (deudextromethorphan hydrobromide / quinidine sulfate)GRIN1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03896945Phase 2/3EfficacyOther
Sep 29, 2026Activity without benefit: KEYNOTE-641 and the limits of PD-1 blockade in prostate cancerPembrolizumab plus enzalutamidePDCD1Merck Sharp & Dohme LLCNCT03834493Phase 3EfficacyOncology
Sep 29, 2026A validated target is not a viable programme: SIM1803-1A and the crowded TRK fusion fieldSIM1803-1ANTRK1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT04671849Phase 1SponsorOncology
Sep 28, 2026Absence of rejection is not evidence of tolerance: CTOT-09 and complete tacrolimus withdrawalTacrolimus (withdrawal)FKBP1ANational Institute of Allergy and Infectious Diseases (NIAID)NCT01517984Phase 2BiomarkerOther
Sep 28, 2026JS207 and the emptying of post-checkpoint lung cancer: a PD-1 x VEGFA bispecific closed after 18 patientsJS207 (PD-1 x VEGFA bispecific antibody)PDCD1Shanghai Junshi Bioscience Co., Ltd.NCT06924606Phase 2SponsorOncology
Sep 27, 2026CTOT-11: B cell depletion at heart transplant accelerated coronary atheromaRituximabMS4A1National Institute of Allergy and Infectious Diseases (NIAID)NCT01278745Phase 2Translational MismatchOther
Sep 27, 2026BL-M11D1: a CD33 conjugate closed at Phase 1 without a posted doseBL-M11D1CD33SystImmune Inc.NCT06714591Phase 1SponsorOncology
Sep 26, 2026STRIVE: ensitrelvir cleared virus in hospitalized COVID-19 and still failed recoveryEnsitrelvir (S-217622)nsp5University of MinnesotaNCT05605093Phase 3EfficacyInfectious Disease
Sep 26, 2026ZEAL: selective ETA blockade lowered blood pressure but not portal pressureZibotentan (ZD-4054) plus dapagliflozinEDNRAAstraZenecaNCT05516498Phase 2EfficacyCardiology
Sep 25, 2026A mask that did not hold: zero responses in 95 patients on TAK-186TAK-186 (MVC-101)EGFRTakedaNCT04844073Phase 1/2EfficacyOncology
Sep 25, 2026The biomarker moved and the bones did not: INZ-701 in ENPP1 deficiencyINZ-701 (BMN 401, rhENPP1-Fc)ENPP1Inozyme Pharma (collaborator BioMarin Pharmaceutical)NCT07473973Phase 3BiomarkerOther
Sep 24, 2026A week 4 futility gate closed on a TRPA1 antagonist whose cough effect appeared at week 12BI 1839100TRPA1Boehringer Ingelheim (industry)NCT06360094Phase 2Translational MismatchOther
Sep 24, 2026Non-depleting anti-CD19 did not move gadolinium-enhancing lesions in relapsing multiple sclerosisLY3541860CD19Eli Lilly and Company (industry)NCT06220669Phase 2EfficacyNeurology
Sep 23, 2026Tumour paint in the mouth: tozuleristide failed to separate oral cancer from normal mucosaTozuleristide (BLZ-100)MMP2University of Washington (collaborator Blaze Bioscience Inc.)NCT05316688Phase 1/2Translational MismatchOncology
Sep 23, 2026Acasunlimab in post-checkpoint NSCLC: a 17.5 month median, then a portfolio decisionAcasunlimab (GEN1046, DuoBody-PD-L1x4-1BB)TNFRSF9GenmabNCT05117242Phase 2SponsorOncology
Sep 22, 2026INFRONT-3: latozinemab raised progranulin 2.6-fold and FTD-GRN progressed anywayLatozinemab (AL001)SORT1Alector Inc. (INDUSTRY), collaborator GlaxoSmithKlineNCT04374136Phase 3Translational MismatchNeurology
Sep 22, 2026POTAMI-61: romaciclib's CDK8/19 route around JAK produced one SVR35 in myelofibrosisRomaciclib (RVU120, SEL120), alone or with ruxolitinibCDK8Ryvu Therapeutics SA (INDUSTRY)NCT06397313Phase 2SponsorOther
Sep 21, 2026MBX-102 (arhalofenate): a PPARγ partial agonist that traded away the efficacy it needed in type 2 diabetesMBX-102 (arhalofenate, JNJ-39659100)PPARGGilead Sciences (INDUSTRY); originally Metabolex, later CymaBay TherapeuticsNCT00814372Phase 2EfficacyMetabolic
Sep 21, 2026KEYLYNK-009: olaparib maintenance in unselected metastatic TNBC matched chemotherapy but never beat itOlaparib (Lynparza, AZD2281) plus pembrolizumabPARP1Merck Sharp & Dohme LLC (INDUSTRY)NCT04191135Phase 2EfficacyOncology
Sep 20, 2026HB-1 failed in panic disorder: a rigorous dismantling design against a target with zero genetic supportHB-1 (telmisartan plus verapamil)AGTR1HB BioTech, LLC (INDUSTRY)NCT06483789Phase 2EfficacyOther
Sep 20, 2026RVU120 monotherapy produced no durable remissions in refractory AML: a Mediator kinase that sensitizes rather than killsRVU120 (romaciclib)CDK8Ryvu Therapeutics SA (INDUSTRY)NCT06268574Phase 2EfficacyOncology
Sep 19, 2026ODYSSEY-HCM: mavacamten cut NT-proBNP by 59 percent and still missed both primary endpointsMavacamten (MYK-461, BMS-986427, Camzyos)MYH7Bristol-Myers Squibb (INDUSTRY)NCT05582395Phase 3Translational MismatchCardiology
Sep 19, 2026GSK3915393 met futility in IPF: a transglutaminase 2 inhibitor with literature-only human supportGSK3915393TGM2GlaxoSmithKline (INDUSTRY)NCT06317285Phase 2EfficacyOther
Sep 18, 2026A systemic myosin inhibitor met a focal disease, and the index was set before dosingMTR-601 (MPH-220)MYH2Motric Bio (INDUSTRY)NCT06830642Phase 2SafetyOther
Sep 18, 2026A sortilin antibody inherited its genetics from the wrong geneNivisnebart (GSK4527226, AL101)SORT1GlaxoSmithKline (INDUSTRY)NCT06079190Phase 2EfficacyNeurology
Sep 17, 2026Batoclimab cleared its Phase 3 endpoint in myasthenia gravis and was shelved anywayBatoclimabFCGRTImmunovant Sciences GmbH (INDUSTRY)NCT05403541Phase 3SponsorOther
Sep 17, 2026ARO-MUC5AC was safe, quiet, and dropped: an inhaled RNAi program with no target engagement readoutARO-MUC5ACMUC5ACArrowhead Pharmaceuticals (INDUSTRY)NCT05292950Phase 1/2SponsorOncology
Sep 16, 2026Pomaglumetad, GRM2 and a genetic signal that pointed at the other receptorPomaglumetad methionil (LY2140023)GRM2Denovo Biopharma LLCNCT01129674Phase 2/3EfficacyOther
Sep 16, 2026ARGX-119 in ALS and the difference between holding a synapse and saving a neuronARGX-119 (adimanebart)MUSKargenxNCT06441682Phase 2Translational MismatchNeurology
Sep 15, 2026Navacaprant and the end of the kappa antagonist thesis in major depressionNavacaprantOPRK1Neumora Therapeutics, Inc.NCT06029439Phase 3EfficacyOther
Sep 15, 2026A validated target that could not be reached: [111In]-FPI-2107 in EGFR-mutant lung cancer[111In]-FPI-2107EGFRAstraZenecaNCT07500987Phase 1Translational MismatchOncology
Sep 14, 2026Ziltivekimab in inflammatory heart failure: the cytokine moved and the events did notZiltivekimabIL6Novo Nordisk A/SNCT05636176Phase 3EfficacyCardiology
Sep 14, 2026Alpha-1 antitrypsin for GVHD prophylaxis: a seven-year trial built on an uncontrolled response rateAlpha-1 antitrypsin (alpha-1 proteinase inhibitor)SERPINA1CSL BehringNCT03805789Phase 2/3SponsorOther
Sep 13, 2026Afabicin in staphylococcal bone and joint infection: six years, 67 patients, no path forwardAfabicin (Debio 1450)fabIDebiopharm International SANCT03723551Phase 2EnrollmentInfectious Disease
Sep 13, 2026Vibostolimab in adjuvant melanoma: toxicity ended the trial before the endpoint couldPembrolizumab/vibostolimab coformulation (MK-7684A)TIGITMerck Sharp & Dohme LLCNCT05665595Phase 3SafetyOncology
Sep 12, 2026Bemarituzumab in FGFR2b-overexpressing gastric cancer: an effect estimate that did not holdBemarituzumabFGFR2AmgenNCT05111626Phase 3EfficacyOncology
Sep 12, 2026Piromelatine in mild Alzheimer's disease: a 2q12 responder signature that did not replicatePiromelatineMTNR1ANeurim Pharmaceuticals Ltd.NCT05267535Phase 2/3BiomarkerNeurology
Sep 10, 2026WVE-004 in C9orf72 ALS and FTD: half the poly-GP, none of the benefitWVE-004C9orf72Wave Life Sciences USA, Inc.NCT05683860Phase 1/2Translational MismatchNeurology
Sep 10, 2026Enpatoran in dermatomyositis: a futility stop that cannot carry the weight put on itEnpatoran (M5049)TLR7EMD Serono Research & Development Institute, Inc. (with Merck KGaA)NCT05650567Phase 2EfficacyOther
Sep 9, 2026SPLENDOUR: RANKL blockade in advanced NSCLC did not reproduce its own exploratory signalDenosumabTNFSF11ETOP IBCSG Partners FoundationNCT02129699Phase 3EfficacyOncology
Sep 9, 2026Volenrelaxin in chronic kidney disease: a Phase 2 withdrawn on the heart failure readoutVolenrelaxin (LY3540378)RXFP1Eli Lilly and CompanyNCT06598631Phase 2Translational MismatchOther
Sep 8, 2026VERSATILE-003: a registrational Phase 3 in HPV16-positive head and neck cancer stopped by the sponsor balance sheetPDS0101 (Versamune HPV) plus pembrolizumabPDCD1PDS Biotechnology Corp.NCT06790966Phase 3SponsorOncology
Sep 8, 2026Sotorasib versus consolidation durvalumab in ctDNA-positive stage III KRAS G12C lung cancer: a trial whose eligible population was defined out of existenceSotorasib (AMG 510)KRASMemorial Sloan Kettering Cancer CenterNCT06333678Phase 2EnrollmentOncology
Sep 7, 2026Merck ended KEYNOTE-057 for business reasons, and the TIGIT question in BCG-unresponsive bladder cancer went with itPembrolizumab/vibostolimab (MK-7684A) and favezelimab/pembrolizumab (MK-4280A) coformulationsTIGITMerck Sharp & Dohme LLCNCT02625961Phase 2SponsorOncology
Sep 7, 2026LEAP-012 bought 4.6 months of progression-free survival in liver cancer and returned a hazard ratio of 0.98 for deathLenvatinib plus pembrolizumab added to transarterial chemoembolizationKDRMerck Sharp & Dohme LLCNCT04246177Phase 3EfficacyOncology
Sep 6, 2026Kyverna closed its scleroderma CAR T trial after three patients, and left the hypothesis untestedKYV-101 (mivocabtagene autoleucel, miv-cel)CD19Kyverna Therapeutics (INDUSTRY)NCT06400303Phase 1/2SponsorOther
Sep 6, 2026Novartis stopped MGY825, and NRF2-mutant lung cancer lost its only clinical-stage inhibitor-direction programMGY825NFE2L2Novartis Pharmaceuticals (INDUSTRY)NCT05275868Phase 1SponsorOncology
Sep 5, 2026Ceralasertib discontinued: an ATR programme that never selected for the dependency it targetedCeralasertibATRAstraZeneca (INDUSTRY)NCT06754761Phase 1SponsorOncology
Sep 5, 2026Aspirin in adjuvant breast cancer: the ABC trial crossed its futility boundAspirinPTGS2Alliance for Clinical Trials in Oncology (OTHER), with National Cancer Institute, United States Department of Defense, Bayer and Canadian Cancer Trials GroupNCT02927249Phase 3EfficacyOncology
Sep 4, 2026Etavopivat in lower-risk MDS: a red cell drug tested in a stem cell diseaseEtavopivatPKLRForma Therapeutics, Inc.NCT05568225Phase 2EfficacyOther
Sep 4, 2026A9-3408 and MC1R: a pigmentation gene borrowed as a delivery address[225Ac]Ac-A9-3408MC1RAlpha-9 Oncology USA Inc.NCT07076550Phase 1SponsorOncology
Sep 3, 2026Pegcetacoplan in delayed graft function: a Phase 3 withdrawn before its first patientPegcetacoplanC3Apellis Pharmaceuticals, Inc.NCT07020832Phase 3SponsorOther
Sep 3, 2026Lasmiditan in pediatric migraine: a placebo-enriched Phase 3 that still could not separateLasmiditanHTR1FEli Lilly and CompanyNCT04396236Phase 3EfficacyOther
Sep 2, 2026A CRAC channel inhibitor in acute kidney injury: the KOURAGE mortality imbalanceZegocractin (Auxora)ORAI1CalciMedica, Inc.NCT06374797Phase 2SafetyOther
Sep 2, 2026Kyverna closed CD19 CAR T in lupus nephritis without an efficacy readoutKYV-101 (mivocabtagene autoleucel)CD19Kyverna TherapeuticsNCT05938725Phase 1/2SponsorImmunology
Sep 1, 2026Ladarixin in recent-onset type 1 diabetes: a subgroup that did not replicateLadarixin (DF2156A)CXCR2Dompe Farmaceutici S.p.ANCT04628481Phase 2EfficacyMetabolic
Sep 1, 2026Camlipixant in refractory chronic cough: a Phase 2b effect size Phase 3 could not reproduceCamlipixant (BLU-5937, GSK5464714)P2RX3GlaxoSmithKlineNCT07684586Phase 1EfficacyOther
Aug 31, 2026ADAM randomised four men in twenty-six months, and the eligibility window is the reasonFollitropin delta (FE 999049, Rekovelle)FSHRFerring PharmaceuticalsNCT05403476Phase 2EnrollmentOther
Aug 31, 2026Niacin moved HDL in stroke patients but not their recovery, and then the funding ran outExtended-release niacin (Niaspan)HCAR2Henry Ford Health SystemNCT00796887Phase 2SponsorOther
Aug 30, 2026ASP1012: an eight-arm oncolytic vaccinia programme that ended with 15 patients dosed and nothing postedASP1012 (VET2-L2), oncolytic vaccinia virus expressing a leptin-IL-2 fusion proteinIL2Astellas Pharma Global Development, Inc.NCT06171178Phase 1SponsorOncology
Aug 30, 2026A 20-patient venetoclax induction pilot in secondary AML stopped at 10, and the interim result was never postedVenetoclax (ABT-199) added to FLAG or CLAG inductionBCL2University of Michigan Rogel Cancer CenterNCT05780879Phase 2EfficacyOther
Aug 29, 2026Talazoparib plus temozolomide in DNA-repair wild-type prostate cancer: toxicity scaled, response did notTalazoparib plus temozolomidePARP1Memorial Sloan Kettering Cancer CenterNCT04019327Phase 1/2Translational MismatchOncology
Aug 29, 2026SIM0348: a TIGIT and PVRIG bispecific closed by business decision before either arm was testedSIM0348 (anti-TIGIT and anti-PVRIG bispecific antibody)PVRIGJiangsu Simcere Pharmaceutical Co., Ltd.NCT05718219Phase 1SponsorOncology
Aug 28, 2026BI 765049 in Asian solid tumours: the regional bridge closed at 21 patients while the B7-H6 programme moved onBI 765049 (B7-H6 by CD3 T-cell engager), alone and with ezabenlimabNCR3LG1Boehringer IngelheimNCT06091930Phase 1SponsorOncology
Aug 28, 2026RELATIVITY-123: stopped for futility, with the enriched co-primary population faring worseRelatlimab-nivolumab fixed-dose combination (BMS-986213)LAG3Bristol-Myers SquibbNCT05328908Phase 3EfficacyOncology
Aug 27, 2026A target that worked, in a molecule that ran out of runwayAcapatamab (AMG 160), PSMA x CD3 half-life extended BiTEFOLH1AmgenNCT04631601Phase 1/2SponsorOncology
Aug 27, 2026A genotype-enriched Phase 3 that the enrichment did not rescueDiamyd (recombinant human GAD65, rhGAD65) in AlhydrogelGAD2Diamyd Medical ABNCT05018585Phase 3BiomarkerMetabolic
Aug 26, 2026Emraclidine's M4 bet ended in a 698-patient extension nobody had a reason to finishEmraclidine (CVL-231, ABBV-1231, PF-06852231)CHRM4AbbVieNCT05443724Phase 2EfficacyOther
Aug 26, 2026Checkpoint blockade accelerated renal medullary carcinomaIpilimumab plus nivolumabCTLA4M.D. Anderson Cancer CenterNCT03274258Phase 2EfficacyOncology
Aug 26, 2026CBX-12 turned a 10-patient signal into a randomized Phase 2 and lost itCBX-12 (alphalex pHLIP-exatecan peptide-drug conjugate)TOP1Cybrexa TherapeuticsNCT06315491Phase 2EfficacyOncology
Aug 26, 2026LEAP-014 added response in metastatic ESCC and no survivalLenvatinib (added to pembrolizumab plus platinum chemotherapy)KDRMerck Sharp & Dohme LLCNCT04949256Phase 3EfficacyOncology
Aug 2, 2026Early hydrocortisone in sepsis stopped for futility, and the timing hypothesis is still untestedHydrocortisone (early low-dose intravenous)NR3C1Siriraj Hospital, Mahidol UniversityNCT06217939UnknownEfficacyInfectious Disease
Aug 2, 2026Camrelizumab plus apatinib could not replace chemotherapy in first-line cervical cancerCamrelizumab (SHR-1210) plus apatinibPDCD1Sun Yat-Sen University Cancer CenterNCT04974944Phase 2EfficacyOncology
Aug 1, 2026Rivoceranib in adenoid cystic carcinoma: RM-202 closed three years after its data, on an endpoint the disease rarely movesRivoceranibKDRElevar TherapeuticsNCT04119453Phase 2SponsorOncology
Aug 1, 2026Eftilagimod alfa in metastatic breast cancer: AIPAC-003 stopped at the lead-in, and the Phase 3 it was meant to feed never openedEftilagimod alfaLAG3Immutep S.A.S.NCT05747794Phase 2/3SponsorOncology
Jul 31, 2026OMX-0407 in pretreated solid tumors: a SIK inhibitor closed the week after its expansion readout windowOMX-0407SIK3iOmx Therapeutics AGNCT05826600Phase 1/2SponsorOncology
Jul 31, 2026ICT01 in advanced solid tumors: EVICTION-2 met its endpoints and was closed by an acquisitionICT01BTN3A1ImCheck Therapeutics, an Ipsen companyNCT05307874Phase 1/2SponsorOncology
Jul 30, 2026Pioglitazone for sympathetic overactivity in CKD: the biomarker the trial was built on was not therePioglitazonePPARGThe University of Texas at ArlingtonNCT03471117UnknownBiomarkerOther
Jul 30, 2026Avelumab plus lenvatinib in children with primary CNS tumors: an adult combination that did not translateAvelumab plus lenvatinibCD274EMD Serono Research & Development Institute, Inc.NCT05081180Phase 1EfficacyOncology
Jul 29, 2026Favezelimab in Hodgkin lymphoma: the LAG-3 trial that was closed by a colorectal cancer readoutFavezelimabLAG3Merck Sharp & Dohme LLCNCT03598608Phase 1/2SponsorOncology
Jul 29, 2026Siplizumab in new-onset type 1 diabetes: a dose-finding study that selected on the wrong half of the pharmacologySiplizumabCD2National Institute of Allergy and Infectious Diseases (NIAID)NCT05574335Phase 1/2Translational MismatchMetabolic
Jul 28, 2026Rocatinlimab in prurigo nodularis: an OX40 program stopped by three Kaposi sarcoma casesRocatinlimabTNFRSF4AmgenNCT06527404Phase 3SafetyOther
Jul 28, 2026Ulixertinib in metastatic uveal melanoma: an ERK inhibitor with no responders in stage 1UlixertinibMAPK1Dana-Farber Cancer InstituteNCT03417739Phase 2EfficacyOncology
Jul 27, 2026Patidegib topical gel stopped in non-Gorlin basal cell carcinoma when the endpoint ran out of eventsPatidegib topical gel 2% (IPI-926)SMOSol-Gel Technologies, Ltd.NCT04155190Phase 2Translational MismatchOncology
Jul 27, 2026innovaTV 205 closed by sponsor decision after five years, with the best-responding arm also the least tolerableTisotumab vedotin (HuMax-TF-ADC)F3Seagen, a wholly owned subsidiary of PfizerNCT03786081Phase 1/2SponsorOncology
Jul 27, 2026Evorpacept plus cetuximab and pembrolizumab stopped in MSS colorectal cancer after two fatal immune activation eventsEvorpacept (ALX148)CD47University of Colorado, DenverNCT05167409Phase 2SafetyOncology
Jul 27, 2026NuCana stopped NUC-3373 across 17 registered tumor types after enrolling 19 patientsNUC-3373 (fosifloxuridine nafalbenamide)TYMSNuCana plcNCT05714553Phase 1/2SponsorOncology
Jul 26, 2026ARTEMIS: terminal complement blockade failed cardiac surgery kidney injury a second timeRavulizumab (ALXN1210)C5Alexion Pharmaceuticals, Inc.NCT05746559Phase 3EfficacyOther
Jul 26, 2026GEN1047 and the B7-H4 T-cell engager problem: 179 patients, no posted resultGEN1047 (DuoBody-CD3-H101GxB7H4)VTCN1GenmabNCT05180474Phase 1/2SponsorOncology
Jul 11, 2026Tolinapant in relapsed/refractory PTCL: an IAP antagonist combination with no tolerable doseTolinapant (ASTX660)BIRC2Taiho Oncology, Inc.NCT05403450Phase 1SafetyOncology
Jul 11, 2026TNO155 (batoprotafib) plus nazartinib in EGFR-mutant lung cancer: an SHP2 plus EGFR doublet ended for strategic reasons after eight yearsBatoprotafib (TNO155) plus nazartinib (EGF816)PTPN11Novartis PharmaceuticalsNCT03114319Phase 1SponsorOncology
Jul 11, 2026MK-6194 in non-segmental vitiligo: a Treg-selective IL-2 mutein that matched placeboMK-6194 (IL-2 mutein)IL2RAMerck Sharp & Dohme LLCNCT06113328Phase 2EfficacyOther
Jul 11, 2026Everolimus plus erlotinib in gemcitabine-refractory pancreatic cancer: mTOR blockade stopped for toxicity and futilityEverolimus (RAD001) plus erlotinibMTORM.D. Anderson Cancer Center (investigator-sponsored; everolimus from Novartis, erlotinib from OSI/Genentech)NCT00640978Phase 2EfficacyOncology
Jul 11, 2026Esmethadone (REL-1017) in major depressive disorder: a low-affinity NMDA blocker whose Phase 3 program stopped at interim re-estimationEsmethadone (REL-1017, dextromethadone)GRIN1Levomecor Inc. (Relmada Therapeutics REL-1017 program)NCT06011577Phase 3EfficacyOther
Jul 8, 2026SAR443579: a CD123 NK-cell engager handed back after modest single-agent remission rates in relapsed AMLSAR443579 (IPH6101)IL3RASanofiNCT05086315Phase 1/2SponsorOncology
Jul 8, 2026SLC-3010: another CD122-biased IL-2 complex shelved in solid tumorsSLC-3010 (hIL-2/TCB2c)IL2SelecxineNCT05525247Phase 1/2SponsorOncology
Jul 8, 2026Obeticholic acid in biliary atresia: a pediatric FXR trial stopped by an adult safety signalObeticholic acid (OCA, Ocaliva)NR1H4Intercept PharmaceuticalsNCT06121375Phase 2/3SafetyOther
Jul 7, 2026TAK-280: a conditional B7-H3 x CD3 T-cell engager that reached cytokine release but not responseTAK-280 (B7-H3 x CD3e COBRA conditional bispecific T-cell engager)CD276TakedaNCT05220098Phase 1/2EfficacyOncology
Jul 7, 2026MK-1167: a business-reason halt for an alpha7 nicotinic modulator in Alzheimer'sMK-1167 (alpha7 nicotinic acetylcholine receptor positive allosteric modulator)CHRNA7Merck Sharp & Dohme LLCNCT06721156Phase 2EfficacyNeurology
Jul 6, 2026GEN1042 with radiotherapy: a CD40x4-1BB bispecific and no abscopal responsesGEN1042 (DuoBody-CD40x4-1BB, BNT312)CD40GenmabNCT05491317Phase 1/2EfficacyOncology
Jul 6, 2026KER-012 in pulmonary arterial hypertension: an activin ligand trap stopped for pericardial effusionsKER-012ACVR2BKeros Therapeutics, Inc.NCT05975905Phase 2SafetyCardiology
Jul 6, 2026Revumenib in colorectal and solid tumors: a menin inhibitor with zero responsesRevumenib (SNDX-5613)MEN1Syndax PharmaceuticalsNCT05731947Phase 1/2EfficacyOncology
Jul 1, 2026Etrasimod in Crohn's disease: CULTIVATE stops after the S1P modulator matches placeboEtrasimod (APD334)S1PR1PfizerNCT04173273Phase 2/Phase 3EfficacyImmunology
Jul 1, 2026Magrolimab in classic Hodgkin lymphoma: a responding trial closed when the CD47 program collapsedMagrolimab (Hu5F9-G4)CD47Ranjana Advani (Stanford University), with Merck Sharp & DohmeNCT04788043Phase 2SponsorOncology
Jun 30, 2026Lebrikizumab in asthma: an anti-IL-13 effect that would not replicateLebrikizumabIL13Hoffmann-La RocheNCT01875003Phase 3EfficacyImmunology
Jun 30, 2026Belapectin in MASH cirrhosis: a subgroup that did not survive its own confirmatory trialBelapectin (GR-MD-02)LGALS3Galectin Therapeutics Inc.NCT04365868Phase 2/3EfficacyCardiology
Jun 30, 2026Valiltramiprosate (ALZ-801) in APOE4/4 Alzheimer's: the oral anti-oligomer bet winds downValiltramiprosate (ALZ-801)APPAlzheon Inc.NCT06304883Phase 3EfficacyNeurology
Jun 29, 2026Brensocatib in hidradenitis suppurativa: a DPP1 inhibitor that worked in bronchiectasis and lost to placebo hereBrensocatibCTSCInsmed IncorporatedNCT06685835Phase 2EfficacyOther
Jun 29, 2026SAR442501 in achondroplasia: an anti-FGFR3 antibody dropped at 16 patients in a crowded fieldSAR442501FGFR3SanofiNCT06067425Phase 2SponsorOther
Jun 26, 2026Pegargiminase in leiomyosarcoma: ARGSARC ends a Phase 3 where the active arm gave up chemotherapyPegargiminase (ADI-PEG 20)ASS1Polaris GroupNCT05712694Phase 3EfficacyOncology
Jun 26, 2026SGN-MesoC2 and the mesothelin question: Pfizer shelves a TOP1 ADC in a target class that keeps disappointingSGN-MesoC2 (PF-08052666)MSLNSeagen (Pfizer)NCT06466187Phase 1SponsorOncology
Jun 24, 2026Brazikumab worked against IL-23 in Crohn's disease, then lost a portfolio decisionBrazikumab (MEDI2070)IL23AAstraZenecaNCT03759288Phase 2/3SponsorImmunology
Jun 24, 2026Bemarituzumab's FGFR2b benefit lived in gastric cancer, so the solid-tumor basket was cutBemarituzumabFGFR2AmgenNCT05325866Phase 1/2SponsorOncology
Jun 23, 2026CLN-617 and the limits of anchoring two cytokines inside a tumorCLN-617IL12BCullinan TherapeuticsNCT06035744Phase 1EfficacyOncology
Jun 23, 2026BND-35 and the myeloid checkpoint that was tested in the wrong tumorsBND-35LILRB4Biond BiologicsNCT06274437Phase 1SponsorOncology
Jun 22, 2026PRS-344/S095012 in solid tumors: a 4-1BB/PD-L1 bispecific stopped in Phase 1PRS-344/S095012TNFRSF9Servier Bio-Innovation LLCNCT05159388Phase 1/2SponsorOncology
Jun 22, 2026Spesolimab in hidradenitis suppurativa: an IL-36 receptor program that worked in pustular psoriasis and stalled hereSpesolimabIL1RL2Boehringer IngelheimNCT06241573Phase 2/3Translational MismatchOther
Jun 22, 2026GSK3965193 in chronic hepatitis B: a PAPD5/7 RNA destabilizer dropped for bepirovirsenGSK3965193PAPD5GlaxoSmithKlineNCT05330455Phase 1/2SponsorInfectious Disease
Jun 22, 2026Pociredir in sickle cell disease: an EED inhibitor halted by a PRC2 class-safety verdictPociredirEEDFulcrum TherapeuticsNCT07431398Phase 1SafetyOther
Jun 20, 2026Vidutolimod in first-line metastatic melanoma: the randomized TLR9 bet that was called offVidutolimod (CMP-001)TLR9Regeneron PharmaceuticalsNCT04695977Phase 2/3SponsorOncology
Jun 20, 2026BE-101 in hemophilia B: a genetically airtight target dropped for strategic reasonsBE-101 (engineered B-cell secreting Factor IX-Padua)F9Be BiopharmaNCT06611436Phase 1/2SponsorOther
Jun 19, 2026XMT-2056, a HER2-directed STING-agonist ADC, ends in Phase 1 after a fatal dose-escalation signal and an acquisitionXMT-2056ERBB2Day One BiopharmaceuticalsNCT05514717Phase 1SponsorOncology
Jun 19, 2026NX-13, NLRX1, and the limits of an agonist with almost no human genetic support in ulcerative colitisNX-13NLRX1AbbVieNCT05785715Phase 2SponsorImmunology
Jun 17, 2026Canakinumab plus chemoimmunotherapy in first-line NSCLC: the CANOPY-1 efficacy failureCanakinumab (ACZ885)IL1BNovartis PharmaceuticalsNCT03631199Phase 3EfficacyOncology
Jun 17, 2026A non-depleting anti-CD19 antibody in rheumatoid arthritis: the LY3541860 interim futilityLY3541860CD19Eli Lilly and CompanyNCT06859294Phase 2EfficacyImmunology
Jun 15, 2026Vidutolimod in skin cancers: a TLR9 agonist whose response collapsed after checkpoint failureVidutolimodTLR9Regeneron PharmaceuticalsNCT04916002Phase 2SponsorOncology
Jun 15, 2026Acasunlimab in melanoma: a PD-L1x4-1BB bispecific shelved before the question could be testedAcasunlimabTNFRSF9GenmabNCT06984328Phase 2SponsorOncology
Jun 15, 2026BBI-825 stopped on its own metabolism, not on RNR biologyBBI-825RRM1Boundless Bio, Inc.NCT06299761Phase 1/2Translational MismatchOncology
Jun 15, 2026Amlitelimab worked in eczema and was dropped in alopecia areataAmlitelimabTNFSF4SanofiNCT06444451Phase 2SponsorImmunology
Jun 15, 2026Poziotinib in exon 20 NSCLC: when preclinical potency outran the therapeutic windowPoziotinibERBB2Spectrum Pharmaceuticals, IncNCT03318939Phase 2Translational MismatchOncology
Jun 12, 2026BBI-355 and the ecDNA bet: a first-in-class CHK1 inhibitor halted on clinical and market groundsBBI-355CHEK1Boundless BioNCT05827614Phase 1SponsorOncology
Jun 12, 2026Brimarafenib plus mirdametinib: a vertical MAPK doublet stopped for tolerabilityBrimarafenib (BGB-3245) plus mirdametinibBRAFSpringWorks TherapeuticsNCT05580770Phase 1/2SafetyOncology
Jun 11, 2026Aticaprant in MDD: target engagement held, clinical efficacy did notAticaprantOPRK1Janssen Research & Development, LLCNCT06635135Phase 3EfficacyOther
Jun 11, 2026ASP1570 in advanced solid tumors: a DGK-zeta brake that read clean in mice and flat in patientsASP1570DGKZAstellas Pharma Global Development, Inc.NCT05083481PHASE1_2EfficacyOncology
Jun 11, 2026Epetraborole in treatment-refractory MAC: a Phase 2 PRO signal that Phase 3 erasedEpetraboroleleuSAN2 Therapeutics, IncNCT05327803PHASE2_3EfficacyInfectious Disease
Jun 11, 2026Tiragolumab in resected NSCLC: an adjuvant trial closed by the class-wide TIGIT collapseTiragolumabTIGITHoffmann-La RocheNCT06267001Phase 3EfficacyOncology
Jun 11, 2026Obeticholic acid plus bezafibrate in PBC: a long-term safety extension ended by a market withdrawalObeticholic acid (OCA) + bezafibrate fixed-dose combinationNR1H4Intercept PharmaceuticalsNCT06488911Phase 3SafetyOther
Jun 9, 2026Vodobatinib in dementia with Lewy bodies: a c-Abl program stopped by the readout next doorVodobatinib (K0706)ABL1Georgetown UniversityNCT03996460Phase 2Translational MismatchNeurology
Jun 9, 2026Soticlestat in Dravet and Lennox-Gastaut syndrome: a CH24H bet that cleared Phase 2 and missed in Phase 3Soticlestat (TAK-935)CYP46A1TakedaNCT05163314Phase 3EfficacyOther
Jun 7, 2026PF-07265807, a dual AXL and MERTK inhibitor, discontinued in Phase 1 solid tumors: a genetically unanchored TAM-kinase bet left without a readoutPF-07265807MERTKPfizerNCT04458259Phase 1SponsorOncology
Jun 7, 2026Lenvatinib plus pembrolizumab in melanoma brain metastases: an antiangiogenic resensitization bet that produced almost no intracranial responsesLenvatinibKDRYale University (collaborator: Merck Sharp & Dohme)NCT04955743Phase 2EfficacyOncology
Jun 6, 2026INCB099280, an oral PD-L1 inhibitor, dropped in Part 1 as Incyte cut its checkpoint pipelineINCB099280 plus axitinibCD274Incyte CorporationNCT05949632Phase 1/2SponsorOncology
Jun 6, 2026Alpelisib plus olaparib failed to beat chemotherapy in platinum-resistant ovarian cancerAlpelisib (BYL719) plus olaparibPIK3CANovartis PharmaceuticalsNCT04729387Phase 3EfficacyOncology
Jun 5, 2026JNJ-95475939, a bispecific IL-4Rα x IL-31 antibody, stopped for futility in atopic dermatitis at the DUPLEX-AD interimJNJ-95475939IL31Janssen Research & Development, LLC (Johnson & Johnson)NCT06881251Phase 2EfficacyOther
Jun 5, 2026VIALE-T, a Phase 3 venetoclax plus azacitidine maintenance trial after transplant in AML, ended on strategic groundsvenetoclaxBCL2AbbVieNCT04161885Phase 3SponsorOncology
Jun 3, 2026Linaprazan glurate: a Phase 3 reflux maintenance trial withdrawn before enrollment on a validated targetLinaprazan glurate (X842)ATP4ACinclus Pharma Holding ABNCT07313774Phase 3SponsorOther
Jun 3, 2026GSK1070806 in atopic dermatitis: when a 44 percent placebo response ends an IL-18 programGSK1070806IL18GlaxoSmithKlineNCT05999799Phase 2EfficacyOther
Jun 3, 2026Eciskafusp alfa (PD1-IL2v): a Phase 1 solid-tumor program stopped at a 4.4% predicted chance of clearing its ORR gateEciskafusp alfa (RO7284755, RG6279)IL2RBHoffmann-La RocheNCT04303858Phase 1EfficacyOncology
Jun 3, 2026Deucravacitinib in hidradenitis suppurativa: a TYK2 pilot that lost its funding at seven patientsDeucravacitinib (BMS-986165)TYK2Beth Israel Deaconess Medical Center (collaborator: Bristol-Myers Squibb)NCT05997277Phase 2SponsorOther
Jun 3, 2026BGB-53038, a pan-KRAS inhibitor, shelved at Phase 1 as BeOne pivots to a degraderBGB-53038KRASBeOne MedicinesNCT06585488Phase 1SponsorOncology
Jun 2, 2026Delocamten in obstructive HCM: BMS halts its own backup myosin inhibitorDelocamten (MYK-224 / BMS-986435)MYH7Bristol-Myers SquibbNCT05556343Phase 2SponsorCardiology
Jun 2, 2026PRO1107, a PTK7 antibody-drug conjugate, ended at 33 patients on benefit-riskPRO1107 (GEN1107)PTK7GenmabNCT06171789Phase 1/2Translational MismatchOncology
Jun 2, 2026Nogapendekin alfa inbakicept met its lymphocyte surrogate but lost its first-line NSCLC Phase 3nogapendekin alfa inbakicept (N-803)IL15ImmunityBio, Inc.NCT03520686Phase 3SponsorOncology
Jun 2, 2026Inhaled treprostinil in PH-COPD: PERFECT stops for harm and the extension closesInhaled treprostinilPTGIRUnited TherapeuticsNCT03794583Phase 3SafetyCardiology
Jun 1, 2026ONO-7018 and the MALT1 paracaspase: a first-in-class inhibitor stopped at nine patientsONO-7018MALT1Ono Pharmaceutical Co., Ltd.NCT05515406Phase 1SponsorOncology
Jun 1, 2026GS-0272 and BTLA agonism: a checkpoint agonist that could not show efficacy in rheumatoid arthritisGS-0272BTLAGilead SciencesNCT06031415Phase 1EfficacyImmunology
May 31, 2026BGB-45035, an oral IRAK4 degrader, was terminated in rheumatoid arthritis for insufficient benefitBGB-45035IRAK4BeiGeneNCT07100938Phase 2EfficacyImmunology
May 31, 2026Bemcentinib plus pacritinib in lung adenocarcinoma ended at 4 patients on drug-supply limitsbemcentinibAXLThe University of Texas Health Science Center at San AntonioNCT06516887Phase 1/2SponsorOncology
May 31, 2026CRD-4730, a CaMKII inhibitor for CPVT1, was halted at 7 patients on a business decisionCRD-4730CAMK2DCardurion Pharmaceuticals, Inc.NCT06005428Phase 2SponsorOther
May 31, 2026Certepetide, an NRP1-engaging tumor-penetration peptide, was halted in the BOLSTER cholangiocarcinoma trialcertepetideNRP1Lisata TherapeuticsNCT05712356Phase 2Translational MismatchOncology
May 30, 2026Govorestat in CMT-SORD: the fifth aldose-reductase shot at a SORD-driven neuropathy gets shelved before enrollmentGovorestatAKR1B1Applied Therapeutics, Inc.NCT07191912PHASE_3SponsorOther
May 30, 2026NBI-921352 in SCN8A-DEE: the only Nav1.6-selective clinical asset gets terminated in extension at n=8NBI-921352 (zandatrigine)SCN8ANeurocrine BiosciencesNCT05226780PHASE_2SponsorOther
May 25, 2026Abemaciclib in HPV-negative HNSCC AIM window trial halted after standard-of-care shift to neoadjuvant immunotherapyAbemaciclib (LY2835219, VERZENIO)CDK6University of ArizonaNCT04169074Phase 2SponsorOncology
May 25, 2026Olutasidenib plus azacitidine in IDH1-mutant higher-risk MDS, CMML, and advanced MPNOlutasidenib (FT-2102, REZLIDHIA)IDH1M.D. Anderson Cancer CenterNCT06597734Phase 2SponsorOncology
May 24, 2026AMAG-423 in severe preeclampsia: a digoxin immune Fab Phase 2b/3a stopped by the DSMB for futilityAMAG-423 (digoxin immune Fab)ATP1A1AMAG Pharmaceuticals, Inc.NCT03008616PHASE2_PHASE3EfficacyOther
May 24, 2026ARO-ANG3 (zodasiran) Phase 2 in HoFH: positive LDL signal, then a quiet business-decision shutdownARO-ANG3 (zodasiran)ANGPTL3Arrowhead PharmaceuticalsNCT05217667Phase 2SponsorMetabolic
May 23, 2026Azenosertib in metastatic triple-negative breast cancer: ZAP-IT closes after Zentalis pulls the program over safetyAzenosertib (ZN-c3)WEE1Filipa Lynce, MD (Dana-Farber Cancer Institute) / Zentalis PharmaceuticalsNCT06351332PHASE1_2SafetyOncology
May 23, 2026MT-1186 oral edaravone in ALS: a Phase 3b extension follows its parent into futilityMT-1186 (oral edaravone)SOD1Tanabe Pharma America, Inc.NCT05151471Phase 3EfficacyNeurology
May 22, 2026BG-60366 in EGFR-mutant NSCLC: a chimeric degrader retired after 33 patients in a saturated landscapeBG-60366EGFRBeOne Medicines (formerly BeiGene)NCT06685718Phase 1SponsorOncology
May 22, 2026OPC-167832 in DBOS and PBOS regimens: the 3-month tuberculosis target slips againOPC-167832 (quabodepistat) within DBOS and PBOS regimensDPRE1Gates Medical Research InstituteNCT05971602Phase 2EfficacyInfectious Disease
May 21, 2026DS-2325a in Netherton syndrome: an anti-KLK5 monoclonal antibody shut down on business groundsDS-2325aKLK5Daiichi SankyoNCT05979831PHASE1_PHASE2SponsorOther
May 21, 2026Lerociclib in HR+/HER2- advanced breast cancer: a clean strategic shutdown in a saturated classLerociclib (G1T38)CDK6EQRx, Inc.NCT05085002Phase 2SponsorOncology
May 20, 2026HexaBody-CD38 (GEN3014) in Relapsed/Refractory Multiple Myeloma: A Better Antibody, A Saturated MarketGEN3014 (HexaBody-CD38)CD38GenmabNCT04824794PHASE1_2SponsorOncology
May 20, 2026Daxdilimab in discoid lupus: Amgen walks away from the ILT7 chairDaxdilimab (HZN-7734, MEDI-7734, VIB7734)LILRA4Amgen (formerly Horizon Therapeutics, originally Viela Bio)NCT05591222Phase 2SponsorImmunology
May 20, 2026INB03 in COVID-19 ARDS: Why a Selective Soluble TNF Strategy Did Not Separate From PlaceboINB03 (XPro1595, pegipanermin)TNFINmune Bio, Inc.NCT04370236PHASE2_3EfficacyInfectious Disease
May 20, 2026TOL-3021 SUNRISE: a proinsulin DNA vaccine ran out of biological roomTOL-3021 (BHT-3021)INSTolerion, Inc.NCT03895437Phase 2EfficacyMetabolic
May 19, 2026MAGNET: lithium in UNC13A-stratified ALS fails the confirmatory testLithium carbonateGSK3BStichting TRICALS FoundationNCT06008249Phase 3BiomarkerNeurology
May 19, 2026Onfasprodil (MIJ821) in MDD with suicidal ideation: an NR2B-selective NMDA antagonist that worked for TRD but matched placebo at 24 hoursOnfasprodil (MIJ821)GRIN2BNovartis PharmaceuticalsNCT04722666Phase 2EfficacyNeurology
May 19, 2026Icovamenib in Type 1 Diabetes: Biomea closes COVALENT-112 after a Phase 2 that was never powered to landIcovamenib (BMF-219)MEN1Biomea Fusion Inc.NCT06152042Phase 2SponsorMetabolic
May 19, 2026AdvanTIG-302: ociperlimab and the slow collapse of TIGIT in NSCLCOciperlimab (BGB-A1217)TIGITBeiGeneNCT04746924Phase 3EfficacyOncology
May 18, 2026Tenecteplase in central retinal artery occlusion: REVISION halts a Phase 3 thrombolysis trial for futilityTenecteplase (originally alteplase, switched in protocol V04)PLATUniversity Hospital TuebingenNCT04965038Phase 3EfficacyNeurology
May 18, 2026Tusamitamab ravtansine in 2L NSCLC: when the antigen is real but the ADC is not enoughTusamitamab ravtansine (SAR408701)CEACAM5SanofiNCT04154956Phase 3EfficacyOncology
May 18, 2026IMSA101 and the quiet retirement of the STING-agonist hypothesis in oncologyIMSA101STING1ImmuneSensor Therapeutics Inc.NCT05846659Phase 2SponsorOncology
May 18, 2026BG-89894 (SYH2039): BeOne pulls a MAT2A inhibitor before it can reportBG-89894 (SYH2039)MAT2ABeOne Medicines (BeiGene)NCT06568614Phase 1SponsorOncology
May 17, 2026Brigimadlin and Brightline-2: Boehringer closes a twenty-year MDM2-p53 betBrigimadlin (BI 907828)MDM2Boehringer IngelheimNCT05512377Phase 2SponsorOncology
May 17, 2026Alpelisib in triple-negative breast cancer: EPIK-B3 ends without a signalAlpelisib (BYL719)PIK3CANovartis PharmaceuticalsNCT04251533Phase 3EnrollmentOncology
May 17, 2026Exicorilant in mCRPC: a fourth failure for the GR-bypass hypothesisExicorilant (CORT125281)NR3C1Corcept TherapeuticsNCT03437941Phase 1/2EfficacyOncology